Results 21 to 30 of about 15,755 (201)

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Therapeutics and Clinical Risk Management, 2023
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Hughes MS, Lentzsch S
doaj  

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Haematologica, 2023
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with ...
Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro   +14 more
doaj   +1 more source

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot   +7 more
doaj   +1 more source

Hulgimüeloomi ravi [PDF]

, 2016
Hematoloogiliste kasvajate esinemise korral on 10–15%-l juhtudest tegu müeloomtõvega (1). Müeloomtõbi ei ole väljaravitav, kuid ravimitega on võimalik aeglustada haiguse progresseerumist, parandada patsientide elukvaliteeti ning pikendada elu. Viie aasta
Hein, Marju, Pintson, Madli
core   +2 more sources

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
doaj   +1 more source

Clinical applications of personalized medicine: a new paradigm and challenge [PDF]

, 2017
The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease.
Borro, Marina, DI SANZO, Mariantonia, Fineschi, Vittorio, Frati, Paola, LA RUSSA, Raffaele, Santurro, Alessandro, Scopetti, Matteo, Simmaco, Maurizio   +7 more
core   +1 more source

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma [PDF]

, 2016
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with ...
Abidi, Alexanian, Attal, Attal, Attal, Attal, Attal, Badros, Baldini, Ballestrero, Barlogie, Barlogie, Barlogie, Barlogie, Barlogie, Bartel, Beaven, Berdeja, Berenson, Bernard Maybury, Bladé, Blanes, Cancer Research UK, Cavo, Cavo, Chauhan, Chen, Child, Chérel, Comenzo, Desikan, Dimopoulos, Dispenzieri, Dispenzieri, Donato, Drayson, Durie, Fenk, Fermand, Fermand, Forsberg, Garfall, Garg, Gay, Giralt, Goel, Gordon Cook, Govindarajan, Green, Guy Pratt, Harousseau, Harousseau, Huang, Jakubowiak, Karthik Ramasamy, Kazmi, Kelly, Knop, Kochenderfer, Kumar, Kwee Yong, Lacy, Ladetto, Lahuerta, Lahuerta, Lebovic, Leleu, Lokhorst, Lokhorst, Lonial, Lonial, Ma, Magarotto, Mai, Maiolino, Marin, Mark, Maude, McCann, McCarthy, Mellqvist, Mihara, Mitsiades, Miyamoto, Moreau, Moreau, Moreau, Morgan, Nair, Nath, Nishihori, Nooka, Orchard, Paiva, Palumbo, Palumbo, Pica, Pineda-Roman, Plesner, Popat, Pulte, Qazilbash, Rabin, Rapoport, Rapoport, Rawstron, Riccardi, Rosenblatt, Roussel, Roussel, Rueff, San Miguel, San-Miguel, Sborov, Scheid, Shi, Sonneveld, Sonneveld, Sonneveld, Sonneveld, Spencer, Spencer, Stewart, Stewart, Tacchetti, Voorhees, Zahradova, Zamagni, Zimmerman   +128 more
core   +2 more sources

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)

Blood Science
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of MM.
Gang An, Zheng Ge, Hongmei Jing, Jing Liu, Guoping Yang, Ru Feng, Zhongyuan Xu, Ming Qi, Jianping Wang, Juanjuan Song, Wei Zhou, Binbin Sun, Dian Zhu, Xi Chen, Canchan Cui, Lugui Qiu   +15 more
doaj   +1 more source

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Journal of Translational Autoimmunity, 2019
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Kristine A. Frerichs, Christie P.M. Verkleij, Patricia W.C. Bosman, Sonja Zweegman, Henny Otten, Niels W.C.J. van de Donk   +5 more
doaj   +1 more source

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party [PDF]

, 2017
Non peer ...
Beguin, Yves, Chevalier, Patrice, Dubois, Valerie, El-Cheikh, Jean, Fegueux, Nathalie, Finke, Juergen, Francois, Sylvie, Garban, Frederic, Garderet, Laurent, Gluckman, Eliane, Iacobelli, Simona, Koster, Linda, Kroeger, Nicolaus, Lioure, Bruno, Maertens, Johan, Maillard, Natacha, Meijer, Ellen, Michallet, Mauricette, Passweg, Jakob, Petersen, Eefke, Ruggeri, Annalisa, Russell, Nigel, Schipperus, Martin, Sobh, Mohamad, Tabrizi, Reza, Tholouli, Eleni, Van Biezen, Anja, Volin, Liisa, von dem Borne, Peter   +28 more
core   +3 more sources